Delphinidins for Health & Longevity - Quick Reference Sheet

Delphinidins for Health & Longevity

Created on 10/19/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Delphinidins are blue-red plant pigments concentrated in maqui berries, bilberries, and blackcurrants, used as oral dietary supplements for post-meal blood sugar control, blood vessel flexibility, and tear production. Human trials test berry extracts rather than isolated delphinidins, providing low-level, indirect, mostly industry-funded evidence, with conflicted cholesterol and long-term blood sugar results. Oral extracts report zero serious adverse events, with attention centered on pre-meal timing and iron separation. (Full Review)

Protocol

Standardized extract dosing
60–450 mg/day orally
60 mg/day MaquiBright (dry eyes), 180 mg/day Delphinol (glycemia/lipids), 450 mg/day Delphinol (oxidative stress); or 320 mg/day purified anthocyanins
Best time of day
30–60 min pre-meal
Administered orally before breakfast, 30 min before carbohydrate meals (200 mg), or 60 min before glucose loads (60–180 mg)
Single versus split dosing
Once or 3× daily
180–450 mg/day once before breakfast, or split into 150 mg three times daily with meals given the 3.34-hour elimination half-life
Time to effect
Tear secretion
4 weeks
Increased tear fluid production at 30–60 mg/day maqui extract
Postprandial glucose blunting and acute FMD increases
60–120 minutes
Post-meal blood sugar and insulin peak blunting and acute blood vessel widening
HbA1c and lipid shifts
8–12 weeks
Long-term blood sugar and lipid changes (conflicted across randomized trials)

Benefits

Contraindications
  • Individuals with diabetes mellitus or taking hypoglycemic medications
  • Patients with stage 5 chronic kidney disease (CKD, progressive loss of kidney function) with estimated glomerular filtration rate (eGFR, a blood measure of kidney filtration) <15 mL/min/1.73 m², or acute kidney injury within 3 months
  • Pregnant or lactating women
  • Patients with prior corneal surgery, severe dry eye with Schirmer's test <5 mm/5 min, or taking oral anticoagulants (warfarin)
Key Interactions
  • Antidiabetic drugs (metformin, glimepiride): Monitor (theoretical)
  • Prescription anticoagulants and antiplatelets (apixaban, clopidogrel): Caution (theoretical)
  • Over-the-counter nonsteroidal anti-inflammatory drugs (aspirin, ibuprofen): Caution (theoretical)
  • Cytochrome P450 3A4 (CYP3A4, a drug-metabolizing liver enzyme) substrates (atorvastatin): Monitor (theoretical)
  • Glucose-lowering and antiplatelet supplements (berberine, alpha-lipoic acid): Monitor (theoretical)
  • Non-heme iron supplements (ferrous sulfate): Caution (theoretical)

Risk & Side Effects

  • High:
  • Medium:
  • Low:
  • Speculative: Mild gastrointestinal discomfort; additive hypoglycemia with antidiabetic therapy; platelet aggregation inhibition and bleeding potentiation

Monitoring

Marker Target Why
Fasting Plasma Glucose and 1-Hour Postprandial Glucose Fasting: 70–99 mg/dL; 1-hour post-meal: reduction from baseline Efficacy marker expected to decrease and safety check for low blood sugar (<70 mg/dL)
Fasting Serum Insulin and HOMA-IR Fasting insulin: 2–20 µIU/mL; HOMA-IR: reduction from baseline Efficacy marker expected to decrease as postprandial and fasting insulin demand declines
HbA1c <5.7% Efficacy marker over 12 weeks in prediabetes and safety check with antidiabetic drugs
Fasting Lipid Panel (LDL-C, HDL-C, Triglycerides) LDL-C <100 mg/dL (<2.59 mmol/L); HDL-C ≥40 mg/dL (≥1.03 mmol/L); Triglycerides <150 mg/dL (<1.70 mmol/L) Efficacy marker expected to change based on delphinidin-predominant trial meta-analyses
Brachial FMD and Carotid-Femoral PWV Increase in FMD and reduction in PWV from baseline Efficacy markers for blood vessel widening and reduced arterial stiffness
Schirmer's Test and Dry Eye Symptom Scores Increase in Schirmer's wetting length and reduction in symptom scores from baseline Efficacy markers when targeting tear secretion and eye dryness

Cadence: Baseline (after 8–12 h fast, plus vascular ultrasound or Schirmer's test); 1–2 weeks for capillary glucose with antidiabetic therapy; 4 weeks for postprandial glucose, tear production, and gastrointestinal tolerability; 12 weeks and every 6 months thereafter for HbA1c, lipids, and endothelial changes.

Qualitative Assessment

  • Ocular surface comfort and visual fatigue: Reduced grittiness, burning, and end-of-day screen fatigue during prolonged digital screen work within 2–4 weeks.
  • Post-meal energy stability: Diminished postprandial drowsiness or reactive energy dips 60–120 minutes after carbohydrate-containing meals.
  • Gastrointestinal and hemostatic tolerance: Absence of post-dose nausea, constipation, or unusual skin bruising.